arrow
H

Hyuk-Sang Kwon

The Catholic University of Korea
H指数:65
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Teneligliptin作为添加疗法在经Empagliflozin和Metformin治疗的患者中的疗效与安全性:一项为期24周、随机、双盲、安慰剂对照的III期临床试验

2026-11-140
OA
Efficacy and Safety of Pregabalin and Alpha-Lipoic Acid Combination in Patients With Painful Diabetic Peripheral Neuropathy: A Randomized, Open-Label, Non-Inferiority, Phase IV Clinical Trial and Subgroup Analysis (OPTIMUM Study)

奥普瑞巴林和α-硫辛酸联合治疗痛性糖尿病周围神经病变的疗效与安全性:一项随机、开放标签、非劣效性、IV期临床研究及亚组分析(OPTIMUM研究)

2026-04-290
OAAI
Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial

西格列汀和恩格列净固定剂量组合作为二甲双胍的加用药物在韩国2型糖尿病患者中的疗效与安全性:一项随机、双盲、多中心、安慰剂对照、III期试验

2026-03-260
OAAI
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial

在三联口服联合治疗控制不佳的2型糖尿病患者中,增加第四种口服降糖药与二甲双胍剂量递增的疗效和安全性 (努力): 一项为期24周的随机,开放标签,多中心试验

2026-02-030
PRE
Photobiomodulation Promotes Early Recovery of Olfactory Function and Modulates Neuroprotective Gene Expression in a Mouse Model of Ischemic Stroke

光生物调节促进缺血性卒中小鼠模型中嗅觉功能的早期恢复并调节神经保护性基因表达

2025-05-130
PRE
Intratumoral delivery of mRNA encoding the endogenous TLR2/6 agonist UNE-C1 induces immunogenic cell death and enhances antitumor activity

肿瘤内递送编码内源性TLR2/6激动剂UNE-C1的mRNA诱导免疫原性细胞死亡并增强抗肿瘤活性

2024-11-280
OAAI